Breadcrumb Navigation [Page Hierarchy]

Section Navigation

Hub welcomes 150th visitor

10 April 2015

The Chase Farm redevelopment hub, which opened its doors last month following the meeting of Enfield planning committee on 12 March, welcomed its 150th visitor on Friday 10 April.

The hub, which provides information about the new hospital, is in front of the Clocktower building at the hospital and is open between midday and 4pm on Wednesdays, Thursdays and Fridays. Visitors can inspect the plans, ask questions and leave feedback.

Feedback to date has been positive, with visitors particularly welcoming the investment in new facilities, the provision of new primary school places in the area and the improvement to the hospital’s energy efficiency.

As well as inviting visitors to the hub, the trust is running a series of tours around the site led by hospital director Fiona Jackson.

More information about the redevelopment hub and the site tours can be found on our website.

ENDS

Notes to editors

On 12 March the Enfield Council planning committee approved the outline planning application for the redevelopment of Chase Farm Hospital. Before the redevelopment can begin the trust and the council must sign a section 106 agreement and conclude discussions on a number of other reserved matters.

Full details of the application can be viewed at http://planningandbuildingcontrol.enfield.gov.uk/online-applications by entering the search term EN2 8JL in the search box. The planning application 14/04574/OUT is the top item.

The Royal Free began as a pioneering organisation and continues to play a leading role in the care of patients. Our mission is to provide world class expertise and local care. In the 21st century, the Royal Free London continues to lead improvements in healthcare.

The Royal Free London attracts patients from across the country and beyond to its specialist services in liver, kidney and bone marrow transplantation, haemophilia, renal, HIV, infectious diseases, plastic surgery, immunology, vascular surgery, cardiology, amyloidosis and scleroderma and we are a member of the academic health science partnership UCLPartners.